NCT05487586

Real-World Study of Ceftazidime Avibactam in China

Real-World Study of Ceftazidime-Avibactam to Characterize the Usage in Clinical Practice

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 220 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.

Detailed description

The recruitment will last for approximately 6 months or until recruitment target is met, and information about treatment will be collected from the patients' medical records. Patients will be followed from CAZ AVI initiation until death, withdraw of the study, 60 days after discharged from the hospitalization, whichever comes first. The endpoint events will be evaluated at: 7 days, 14 days, 21 days, 30 days, 60 days, and end of treatment (EOT) after CAZ AVI initiation, if patients are not discharged prior to the next upcoming timepoint; and 30 days, 60 days after discharge.

Conditions

• Hospital Acquired Pneumonia
• Ventilator Acquired Pneumonia
• Complicated Intra Abdominal Infections

Interventions

Type	Name	Description
DRUG	ceftazidime avibactam group	Non-Interventional Study

Timeline

• Start date: 2022-10-20
• Primary completion: 2024-07-11
• Completion: 2024-07-11
• First posted: 2022-08-04
• Last updated: 2025-09-04
• Results posted: 2025-09-04

Locations

17 sites across 1 country: China

Regulatory

• FDA-regulated drug study